| Study | Category of Trial | Enrollment Status |
|---|---|---|
| A5128: US Genomic Sampling Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. |
Non-Interventional | Temporarily Closed Due to COVID-19 |
| A5243: Non-US Genomic Sampling Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. |
Non-Interventional | Temporarily Closed Due to COVID-19 |
| A5300B:Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx) This trial is in household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which is an infection that does not get better with standard treatment for TB. |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications). |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) You are being asked to take part in this research study because you are infected with HIV, the virus that causes AIDS, and were previously followed in the ALLRT (A5001) study and are 40 years of age or older. |
Treatment Experienced | Closed to Accrual |
| A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5324 is a study for persons with HIV with undetectable HIV viral load who have mild neurocognitive impairment. |
Treatment Experienced | Closed to Accrual |
| A5332: REPRIEVE Trial In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication. |
Treatment Experienced | Closed to Accrual |
| A5343: A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis This is a randomized study, which means, by chance, you will be in one of three groups. |
Treatment ExperiencedTuberculosis | Closed to Accrual |
| A5345: HIV Rebound & Control Biomarkers Uses data collected during intensively monitored antiretroviral pauses, where participants stop taking anti-HIV medications until they meet criteria for restarting them. |
Treatment Experienced | Closed to Accrual |
| A5354: Early ART in Acute HIV Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus. |
Treatment Naïve | Closed to Accrual |
| A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults This study is for people with HIV who have an undetectable viral load. |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5359: The LATITUDE Study Investigating whether long-acting injectable medications will be more successful for people who are non-adherent to their HIV medications than oral regimens. |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants Full Title: “A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to Chronically Infected HCV Treatment Naïve Populations Globally: The MINMON Study” Scientists are looking at ways to simplify Hepatitis C (HCV) treatment. |
Treatment NaïveHepatitis | Closed to Accrual |
| A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of strength or walking speed. |
Treatment Experienced | Closed to Accrual |
| A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure of HIV from the body has not been possible. |
Women | Closed to Accrual |
| A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy “Safety and Immunotherapeutic Activity of Cemiplimab in Participants with HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study” Brief Description: Scientists are looking at ways to cure Hepatitis B (HBV). |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5369: p24CE Vaccine Study Evaluating the safety and effectiveness of a new HIV vaccine. |
Treatment Experienced | Closed to Accrual |
| A5370: Anti-PD-1 Antibody in HIV-1 Brief Announcement Regarding A5370 The AIDS Clinical Trials Group (ACTG) Protocol A5370, Version 1. |
Treatment Experienced | Closed to Accrual |
| A5375: Optimize LNG EC Will determine if a higher dose of levonorgestrel Emergency Contraception (commonly called “Plan B” or the “Morning After Pill”) is needed to achieve high enough drug levels in girls and women who are taking anti-HIV medications that are known to decrease the effectiveness of this form of birth control. |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5377: Tri-specific Antibody The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and tolerable and will measure the amount of SAR441236 in the blood over time. |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) This is a study to treat participants, with or without HIV, who are found to have been recently infected with the Hepatitis C virus (HCV). |
Hepatitis | Temporarily Closed Due to COVID-19 |
| A5381: Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy (ART, group of medicine used to treat HIV). |
Treatment Experienced | Temporarily Closed Due to COVID-19 |
| A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 Study Description COVID-19 is a new illness caused by the severe acute respiratory syndrome coronavirus (SARS CoV-2). |
COVID-19 | Closed to Accrual |
Categories of Trials
The ACTG conducts offers a wide range of studies for people infected with HIV. Below is a list of different kinds of clinical trials.
Treatment Naïve
Treatment Naïve refers to people who have never taken HIV medications before. These studies are designed to help find out what treatments or drugs work best as an initial regimen.
Treatment Experienced
Treatment Experienced refers to people who are currently on medications or have taken medications in the past for HIV. Each study has a unique approach: Which are the best medications to treat with? When is the best time to change medications? How do we know when to change medications?
Immunity Enhancers
HIV harms the immune system. These studies look at innovative ways to help your immune system work better while continuing to treat you with HIV medications.
Women
Women with HIV have unique gynecology, maternity, and metabolic issues. These studies are dedicated to fostering the health of women.
Opportunistic Infections
When people with HIV have an additional infection like cytomegalovirus or tuberculosis, there are important treatment questions and side effects to look for. These studies are looking at that unique situation.
Hepatitis
People with HIV may also be infected with Hepatitis. These trials study the treatment of individuals with Hepatitis or individuals with Hepatitis and HIV.
Neurologic Complications
HIV infection may cause nervous system problems such as numbness and cognitive problems. These studies look at treatments for the problems.
Side Effects
We know that many drugs used to successfully treat HIV have side effects. The following studies look at ways to treat the most common of these side effects.
Tuberculosis
People with HIV may also be infected with Tuberculosis. These trials study the diagnosis and treatment of individuals with Tuberculosis.
Non-Interventional
Studies in this section are those in which no attempt is made to affect the outcome of HIV treatment, for example, no treatment is prescribed or provided by the study. People who enter these studies may be asked to provide blood or other biological specimens. They may be asked to complete clinical evaluations and questionnaires. The information from these studies might prove useful in evaluating current or future treatment for people living with HIV.
HIV/Malaria
People with HIV may also be infected with Malaria. These trials study the treatment of individuals with Malaria or individuals with Malaria and HIV.